Devon Energy (DVN) Coveraged By Piper Jaffray with $48.0000 Target, Biospecifics Technologies Has 1.26 Sentiment

July 17, 2017 - By Maria Brooks

Among 30 analysts covering Devon Energy Corporation (NYSE:DVN), 20 have Buy rating, 0 Sell and 10 Hold. Therefore 67% are positive. Devon Energy Corporation has $80 highest and $26 lowest target. $46’s average target is 42.55% above currents $32.27 stock price. Devon Energy Corporation had 75 analyst reports since July 21, 2015 according to SRatingsIntel. The stock has “Market Perform” rating by Bernstein on Thursday, July 6. On Friday, April 15 the stock rating was upgraded by Evercore to “Buy”. The company was maintained on Wednesday, May 4 by JP Morgan. The rating was maintained by iBERIA Capital Partners on Tuesday, March 8 with “Sector Perform”. The firm has “Buy” rating given on Thursday, July 13 by Stifel Nicolaus. The stock of Devon Energy Corp (NYSE:DVN) has “Sector Perform” rating given on Thursday, August 6 by Peters & Co. The firm has “Buy” rating given on Tuesday, March 29 by Deutsche Bank. Barclays Capital maintained the shares of DVN in report on Friday, February 19 with “Overweight” rating. The firm has “Buy” rating by Citigroup given on Monday, July 18. Jefferies maintained the stock with “Hold” rating in Tuesday, July 4 report.

BioSpecifics Technologies Corp. is a biopharmaceutical firm involved in the development of an injectable collagenase clostridium histolyticum for multiple indications. The company has market cap of $371.78 million. The Firm has a development and license agreement with Endo Global Ventures, a Bermuda unlimited liability firm , an affiliate of Endo International plc (Endo), for injectable collagenase for marketed indications and indications in development. It has a 31.29 P/E ratio. Injectable collagenase clostridium histolyticum is marketed as XIAFLEX (or Xiapex in Europe).

About 10 shares traded. Devon Energy Corp (NYSE:DVN) has risen 13.24% since July 17, 2016 and is uptrending. It has underperformed by 3.46% the S&P500.

Devon Energy Corporation is an independent energy company. The company has market cap of $16.88 billion. The Firm also controls EnLink Midstream Partners, L.P. . It has a 31.75 P/E ratio. The Company’s divisions include U.S., Canada and EnLink.

Investors sentiment increased to 0.92 in 2016 Q4. Its up 0.03, from 0.89 in 2016Q3. It increased, as 48 investors sold Devon Energy Corp shares while 271 reduced holdings. 72 funds opened positions while 223 raised stakes. 403.62 million shares or 2.20% more from 394.94 million shares in 2016Q3 were reported. Salem Counselors accumulated 60,790 shares or 0.32% of the stock. Northwestern Mutual Wealth Mngmt holds 9,616 shares or 0% of its portfolio. Airain reported 1.78% in Devon Energy Corp (NYSE:DVN). 229 are owned by Vantage Investment Advisors Limited Company. Community Commercial Bank Na has 0.01% invested in Devon Energy Corp (NYSE:DVN). Mason Street Ltd Limited Liability Company stated it has 71,626 shares. Legal And General Group Pcl reported 2.66 million shares stake. Steinberg Glob Asset Management accumulated 11,538 shares. Reliance Trust Company Of Delaware accumulated 5,758 shares or 0.04% of the stock. Wafra Invest Advisory Ny accumulated 1.04% or 422,554 shares. Associated Banc owns 9,824 shares for 0.03% of their portfolio. Amica Mutual accumulated 0.13% or 30,990 shares. Carroll Financial Associates holds 0.01% or 1,171 shares. Headinvest Lc stated it has 0.41% in Devon Energy Corp (NYSE:DVN). 47,231 are held by Ingalls & Snyder Lc.

Analysts await Devon Energy Corp (NYSE:DVN) to report earnings on August, 1 after the close. They expect $0.38 earnings per share, up 533.33% or $0.32 from last year’s $0.06 per share. DVN’s profit will be $198.77M for 21.23 P/E if the $0.38 EPS becomes a reality. After $0.41 actual earnings per share reported by Devon Energy Corp for the previous quarter, Wall Street now forecasts -7.32% negative EPS growth.

Analysts await BioSpecifics Technologies Corp. (NASDAQ:BSTC) to report earnings on August, 8. They expect $0.39 earnings per share, up 11.43% or $0.04 from last year’s $0.35 per share. BSTC’s profit will be $2.84 million for 32.76 P/E if the $0.39 EPS becomes a reality. After $0.46 actual earnings per share reported by BioSpecifics Technologies Corp. for the previous quarter, Wall Street now forecasts -15.22% negative EPS growth.

The stock increased 1.45% or $0.73 on July 14, reaching $51.1. About shares traded. BioSpecifics Technologies Corp. (BSTC) has risen 49.91% since July 17, 2016 and is uptrending. It has outperformed by 33.21% the S&P500.

Jw Asset Management Llc holds 2.73% of its portfolio in BioSpecifics Technologies Corp. for 73,649 shares. Rk Capital Management Llc owns 70,801 shares or 0.82% of their US portfolio. Moreover, Northpointe Capital Llc has 0.71% invested in the company for 127,277 shares. The Colorado-based Elk Creek Partners Llc has invested 0.55% in the stock. Tfs Capital Llc, a Pennsylvania-based fund reported 32,873 shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.